Skip to main content

Immunovant, Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

IMVT$35.15+15.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Incorporated by Reference
ExhibitNumberDescriptionFormFile No.ExhibitFiling Date
2.1+Share Exchange Agreement, dated September 29, 2019, by and among Immunovant Sciences Ltd., the stockholders of Immunovant Sciences Ltd., Roivant Sciences Ltd., and Health Sciences Acquisitions Corporation.8-K001-389062.1October 2, 2019
3.1Amended and Restated Certificate of Incorporation of Immunovant, Inc.8-K001-389063.1December 20, 2019
3.2Amended and Restated Bylaws of Immunovant, Inc.8-K001-389063.2December 20, 2019
10.1†Employment Agreement with Eric Venker, dated as of July 28, 2025.10-Q001-3890610.4August 11, 2025
31.1*Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1#Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2#Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents
104*Cover Page Interactive Data (embedded within the Inline XBRL document)
  • Filed herewith.
  • The annexes, schedules, and certain exhibits to the Share Exchange Agreement have been omitted pursuant to
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.